ecrin-mdr-crcClinical2020IPD Sharing (as of June 2022): NoNon-Small Cell Lung CancerEndometrial cancerHER2 Positive Solid TumorsGastrointestinal CancerGastric CancerColorectal CancerHead and neck cancerBreast CancerNeoplasmsEndometrial CancerGastrointestinal CancerGastric CancerColorectal CancerNon-small Cell Lung CancerHer2 Positive Solid TumorsHead And Neck CancerBreast CancerNeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2344768South KoreaUnited StatesAustralia7Stomach CancerUrothelial cancerTLR8 agonistAnti-PD-1 mAbBiliary tract cancerTriple Negative Breast CancerMonoclonal antibodyAntibody drug conjugatePembrolizumabGastroesophageal junctionImmunotherapyERBB2CemiplimabTLR8HER2ECRIN MDRActive, not recruitingfalseA Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid TumorsA first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies2020-07-152344768NCT04460456